Abstract: A system for processing samples by a robotic platform has a tray that defines a well defining a drain. The well has a bottom surface, an access port in fluid communication with the drain, and an insert adapted to be received in the well. The insert has a bottom wall and a side wall. At least one of the bottom wall and the side wall define a plurality of openings, such that an interior of the insert is in fluid communication with the well when the insert is inserted into the well.

Abstract: A system for processing samples by a robotic platform has a tray that defines a well defining a drain. The well has a bottom surface, an access port in fluid communication with the drain, and an insert adapted to be received in the well. The insert has a bottom wall and a side wall. At least one of the bottom wall and the side wall define a plurality of openings, such that an interior of the insert is in fluid communication with the well when the insert is inserted into the well.

Abstract: A system for processing samples by a robotic platform has a tray that defines a well defining a drain. The well has a bottom surface, an access port in fluid communication with the drain, and an insert adapted to be received in the well. The insert has a bottom wall and a side wall. At least one of the bottom wall and the side wall define a plurality of openings, such that an interior of the insert is in fluid communication with the well when the insert is inserted into the well.

Abstract: A system for processing samples by a robotic platform has a tray that defines a well defining a drain. The well has a bottom surface, an access port in fluid communication with the drain, and an insert adapted to be received in the well. The insert has a bottom wall and a side wall. At least one of the bottom wall and the side wall define a plurality of openings, such that an interior of the insert is in fluid communication with the well when the insert is inserted into the well.

Abstract: Disclosed is a therapeutic method for inhibiting development or growth of tumors that are resistant to the blockade of delta-like ligand 4 (Dll4), or vascular endothelial growth factor (VEGF), or to other therapeutic agents, by administering the combination of Dll4 antagonist and VEGF antagonist. The combined administration of these two agents, concurrently or sequentially, exhibits synergistic effects on blood vessel development and growth, thereby more effectively inhibiting the tumor growth than an administration of either agent alone. The Dll4 antagonist can be an anti-Dll4 antibody or antibody fragment capable of inhibiting the binding of Dll4 to a Notch receptor, or a fusion protein comprising the extracellular domain of Dll4 or a soluble Notch receptor, or a fragment thereof, fused to a multimerizing component. The VEGF antagonist can be a VEGF trap, anti-VEGF antibody or antibody fragment capable of inhibiting the binding of VEGF to a VEGF receptor.

Abstract: Disclosed is a therapeutic method for inhibiting development or growth of tumors that are resistant to the blockade of delta-like ligand 4 (Dll4), or vascular endothelial growth factor (VEGF), or to other therapeutic agents, by administering the combination of Dll4 antagonist and VEGF antagonist. The combined administration of these two agents, concurrently or sequentially, exhibits synergistic effects on blood vessel development and growth, thereby more effectively inhibiting the tumor growth than an administration of either agent alone. The Dll4 antagonist can be an anti-Dll4 antibody or antibody fragment capable of inhibiting the binding of Dll4 to a Notch receptor, or a fusion protein comprising the extracellular domain of Dll4 or a soluble Notch receptor, or a fragment thereof, fused to a multimerizing component. The VEGF antagonist can be a VEGF trap, anti-VEGF antibody or antibody fragment capable of inhibiting the binding of VEGF to a VEGF receptor.

Abstract: A therapeutic method for inhibiting tumor development or growth, comprising administering an agent capable of inhibiting human delta-like ligand 4 (DII4) activity to a subject in need thereof. In one embodiment, the agent is an anti-DII4 antibody or antibody fragment capable of inhibiting the binding of DII4 to a Notch receptor. In another embodiment, the agent is a fusion protein comprising the extracellular domain of DII4 or a fragment or variant thereof, fused to a multimerizing component such as an Fc domain. The method of the invention is useful for inhibiting tumor growth, particularly in tumors which are not responsive to other therapeutic agents.

Abstract: Methods for screening for agents capable of inhibiting Dll4 are provided, as well as therapeutic methods for treating Dll4-mediated conditions. More specifically, methods are provided for identifying agents capable of inhibiting blood vessel growth and formation, such as antibodies to human DLL4.

Abstract: A system and method provide for producing and/or implementing a virtual device enabled electronic document. The electronic document includes documentary information and one or more virtual device initiators corresponding to the same or different target devices, or further, to device systems. At least a portion of the documentary information and a corresponding virtual device initiator, in one embodiment, correspond to at least one device operation of the device. A user invoking a virtual device initiator, in one embodiment, causes a document system to configure and initiate a virtual device, or further, other system devices with which the virtual device may interact.

Abstract: Methods of inducing formation of functional and organized lymphatic vessels are described. Specifically, the methods relate to using Tie2 agonists to induce formation of functional and organized lymphatic vessels. The methods also relate to treating defects, diseases, and disorders characterized by lymphatic vessel malfunction, disorganization, and damage.